Exelixis Announces November 7th Webcast of Third Quarter 2012 Financial Results Conference Call
Exelixis Announces November 7thWebcast of Third Quarter 2012 Financial Results Conference Call
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Exelixis, Inc. (NAS: EXEL) will release its third quarter 2012 financial results on Wednesday, November 7, 2012, after the markets close. The announcement will be followed by a live webcast at 5:00 p.m. EST/ 2:00 p.m. PST. During the webcast, Exelixis management will discuss the Company's financial results, financial outlook, and development program and plans for cabozantinib, and also provide a general business update. The webcast may be accessed in the Event Calendar page under Investors at http://www.exelixis.com.
An archived replay of the webcast will be available on the Event Calendar page under Investors at http://www.exelixis.com and via phone until 11:59 p.m. PST on December 7, 2012. Access numbers for the phone replay are: 888-286-8010 (domestic) and 617-801-6888 (international); the passcode is 43220636.
Exelixis, Inc. is a biotechnology company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its proprietary resources and development efforts exclusively on cabozantinib (formerly known as XL184), its most advanced product candidate, in order to maximize the therapeutic and commercial potential of this compound. Exelixis has also established a portfolio of other novel compounds that it believes have the potential to address serious unmet medical needs, many of which are being advanced by partners as part of collaborations. For more information, please visit the company's web site at www.exelixis.com.
Charles Butler, 650-837-7277
Vice President, Investor Relations and Corporate Communications
KEYWORDS: United States North America California
The article Exelixis Announces November 7th Webcast of Third Quarter 2012 Financial Results Conference Call originally appeared on Fool.com.Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.